CTLA4 and neoplasm: More strikingly, the Anti-CTLA4 following LRT gave rise to significant growth delay, and in the sequential model, some of the secondary tumors (3/9) were completely rejected (Fig. 1A & 1B, right panels), while treatment with Anti-CTLA4 alone had no effect on tumor growth.